Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference

HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases, today announced that Anthera Pharmaceuticals will present at the 30th Annual ROTH Capital Partners Conference.  Craig Thompson, President & CEO, is scheduled to present on March 12, 2018 at 11:00am PT.

The presentation will be available via the investor relations section of the Company’s website at www.anthera.com following the live presentation.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases, including IgA nephropathy. Additional information on the Company can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.   Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2017.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT:

Investor Relations of Anthera Pharmaceuticals, Inc.[email protected]

For Media Inquiries:Frannie Marmorstein, 305-567-0821[email protected] www.twitter.com/antherapharmahttps://www.facebook.com/antherapharma/ https://www.linkedin.com/company/anthera-pharmaceuticals

Source: Anthera Pharmaceuticals, Inc.

Source: Anthera Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Enovis to acquire eCential Robotics for up to €211M
• Change Agents completes phase 2 of its AI video platform Catch-Up
• TXNM Energy prices $400 million stock offering at $56.50 per share